

# Vincenzo Calderone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3085495/publications.pdf>

Version: 2024-02-01

202  
papers

5,995  
citations

57631

44  
h-index

118652

62  
g-index

219  
all docs

219  
docs citations

219  
times ranked

6315  
citing authors

#	ARTICLE	IF	CITATIONS
1	Arachidonic Acid Derivatives and Neuroinflammation. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 118-129.	0.8	19
2	H <sub>2</sub> S donating corticosteroids: Design, synthesis and biological evaluation in a murine model of asthma. <i>Journal of Advanced Research</i> , 2022, 35, 267-277.	4.4	17
3	Virtual Combinatorial Library Screening of Quinadoline B Derivatives against SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Computation</i> , 2022, 10, 7.	1.0	12
4	Kv7.4 channels regulate potassium permeability in neuronal mitochondria. <i>Biochemical Pharmacology</i> , 2022, 197, 114931.	2.0	8
5	Glucoraphanin Increases Intracellular Hydrogen Sulfide (H <sub>2</sub> S) Levels and Stimulates Osteogenic Differentiation in Human Mesenchymal Stromal Cell. <i>Nutrients</i> , 2022, 14, 435.	1.7	5
6	Beneficial Effects of <i>Eruca sativa</i> Defatted Seed Meal on Visceral Pain and Intestinal Damage Resulting from Colitis in Rats. <i>Foods</i> , 2022, 11, 580.	1.9	4
7	New Synthetic Analogues of Natural Polyphenols as Sirtuin 1-Activating Compounds. <i>Pharmaceuticals</i> , 2022, 15, 339.	1.7	3
8	Design and Synthesis of New Oligopeptidic Parvulin Inhibitors. <i>ChemMedChem</i> , 2022, , .	1.6	3
9	Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1506.	1.0	11
10	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 667-684.	2.5	15
11	Potential Effects of Natural H <sub>2</sub> S-Donors in Hypertension Management. <i>Biomolecules</i> , 2022, 12, 581.	1.8	16
12	Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases. <i>Molecules</i> , 2022, 27, 2561.	1.7	17
13	Cardiovascular benefits of <i>Eruca sativa</i> mill. Defatted seed meal extract: Potential role of hydrogen sulfide. <i>Phytotherapy Research</i> , 2022, 36, 2616-2627.	2.8	13
14	In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). <i>Computation</i> , 2022, 10, 69.	1.0	3
15	Inhibitors of Mitochondrial Human Carbonic Anhydrases VA and VB as a Therapeutic Strategy against Paclitaxel-Induced Neuropathic Pain in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6229.	1.8	8
16	Structure-activity relationships study of isothiocyanates for H <sub>2</sub> S releasing properties: 3-Pyridyl-isothiocyanate as a new promising cardioprotective agent. <i>Journal of Advanced Research</i> , 2021, 27, 41-53.	4.4	28
17	Role of hydrogen sulfide in endothelial dysfunction: Pathophysiology and therapeutic approaches. <i>Journal of Advanced Research</i> , 2021, 27, 99-113.	4.4	64
18	Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 411-427.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Pharmacological modulation of the hydrogen sulfide ( $H_2S$ ) system by dietary $H_2S$ -donors: A novel promising strategy in the prevention and treatment of type 2 diabetes mellitus. <i>Phytotherapy Research</i> , 2021, 35, 1817-1846.	2.8	17
20	<i>Eruca sativa</i> Mill. seed extract promotes anti-obesity and hypoglycemic effects in mice fed with a high-fat diet. <i>Phytotherapy Research</i> , 2021, 35, 1983-1990.	2.8	15
21	Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112983.	2.6	4
22	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , 2021, 41, 1890-1926.	5.0	28
23	The ïrisin system: From biological roles to pharmacological and nutraceutical perspectives. <i>Life Sciences</i> , 2021, 267, 118954.	2.0	29
24	Synthesis and pharmacological characterization of mitochondrial KATP channel openers with enhanced mitochondriotropic effects. <i>Bioorganic Chemistry</i> , 2021, 107, 104572.	2.0	10
25	Vascular Effects of the Polyphenolic Nutraceutical Supplement Tauriso: Focus on the Protection of the Endothelial Function. <i>Nutrients</i> , 2021, 13, 1540.	1.7	15
26	Contribution of irisin pathway in protective effects of mandarin juice ( <i>Citrus</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (reti Research, 2021, 35, 4324-4333.	2.8	11
27	Modulation of EndMT by Hydrogen Sulfide in the Prevention of Cardiovascular Fibrosis. <i>Antioxidants</i> , 2021, 10, 910.	2.2	24
28	The H <sub>2</sub> S-Donor Erucin Exhibits Protective Effects against Vascular Inflammation in Human Endothelial and Smooth Muscle Cells. <i>Antioxidants</i> , 2021, 10, 961.	2.2	24
29	Protective Effects Induced by a Hydroalcoholic <i>Allium sativum</i> Extract in Isolated Mouse Heart. <i>Nutrients</i> , 2021, 13, 2332.	1.7	15
30	Pharmacological evaluation of innovative eye drop formulations containing TS-polysaccharide, hyaluronic acid and glycyrrhizin for irritative ocular diseases using in vitro reconstituted human corneal epithelium model. <i>Toxicology in Vitro</i> , 2021, 75, 105199.	1.1	0
31	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 748021.	1.6	13
32	Hybrids between H <sub>2</sub> S-donors and betamethasone 17-valerate or triamcinolone acetonide inhibit mast cell degranulation and promote hyperpolarization of bronchial smooth muscle cells. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113517.	2.6	10
33	Identification of novel SIRT1 activators endowed with cardioprotective profile. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 165, 105930.	1.9	5
34	Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. <i>Computers in Biology and Medicine</i> , 2021, 137, 104808.	3.9	22
35	Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1715.	2.0	88
36	Anomalous $K_v7$ channel activity in human malignant hyperthermia syndrome unmasks a key role for $H_2S$ and persulfidation in skeletal muscle. <i>British Journal of Pharmacology</i> , 2020, 177, 810-823.	2.7	16

#	ARTICLE	IF	CITATIONS
37	Erucin exhibits vasorelaxing effects and antihypertensive activity by H <sub>2</sub> S-releasing properties. <i>British Journal of Pharmacology</i> , 2020, 177, 824-835.	2.7	50
38	Organic Isothiocyanates as Hydrogen Sulfide Donors. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 110-144.	2.5	51
39	Protective Effects of Bergamot ( <i>Citrus bergamia</i> Risso & Poiteau) Juice in Rats Fed with High-Fat Diet. <i>Planta Medica</i> , 2020, 86, 180-189.	0.7	14
40	By-Products from Winemaking and Olive Mill Value Chains for the Enrichment of Refined Olive Oil: Technological Challenges and Nutraceutical Features. <i>Foods</i> , 2020, 9, 1390.	1.9	13
41	Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?. <i>Frontiers in Pharmacology</i> , 2020, 11, 1085.	1.6	20
42	Development of In Vitro Corneal Models: Opportunity for Pharmacological Testing. <i>Methods and Protocols</i> , 2020, 3, 74.	0.9	5
43	Cinnamides Target <i>Leishmania amazonensis</i> Arginase Selectively. <i>Molecules</i> , 2020, 25, 5271.	1.7	15
44	Role of hydrogen sulfide in cardiovascular ageing. <i>Pharmacological Research</i> , 2020, 160, 105125.	3.1	35
45	Amyloid $\beta$ fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. <i>Food and Function</i> , 2020, 11, 8122-8132.	2.1	21
46	Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H <sub>2</sub> S donors in COVID-19 therapy. <i>British Journal of Pharmacology</i> , 2020, 177, 4931-4941.	2.7	63
47	Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1178-1179.	1.1	8
48	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	1.8	24
49	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , 2020, 191, 101806.	2.8	87
50	Searching for novel hydrogen sulfide donors: The vascular effects of two thiourea derivatives. <i>Pharmacological Research</i> , 2020, 159, 105039.	3.1	22
51	Development of Fortified Citrus Olive Oils: From Their Production to Their Nutraceutical Properties on the Cardiovascular System. <i>Nutrients</i> , 2020, 12, 1557.	1.7	16
52	The Citrus Flavonoid Naringenin Protects the Myocardium from Ageing-Dependent Dysfunction: Potential Role of SIRT1. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	1.9	52
53	Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. <i>Molecules</i> , 2020, 25, 1952.	1.7	15
54	A Nutraceutical Strategy to Slowing Down the Progression of Cone Death in an Animal Model of Retinitis Pigmentosa. <i>Frontiers in Neuroscience</i> , 2019, 13, 461.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Vascular Effects of H <sub>2</sub> S-Donors: Fluorimetric Detection of H <sub>2</sub> S Generation and Ion Channel Activation in Human Aortic Smooth Muscle Cells. <i>Methods in Molecular Biology</i> , 2019, 2007, 79-87.	0.4	15
56	A New Calcium Oral Controlled-Release System Based on Zeolite for Prevention of Osteoporosis. <i>Nutrients</i> , 2019, 11, 2467.	1.7	3
57	The Nutraceutical Value of Olive Oil and Its Bioactive Constituents on the Cardiovascular System. Focusing on Main Strategies to Slow Down Its Quality Decay during Production and Storage. <i>Nutrients</i> , 2019, 11, 1962.	1.7	38
58	Eruca sativa Meal against Diabetic Neuropathic Pain: An H <sub>2</sub> S-Mediated Effect of Glucoerucin. <i>Molecules</i> , 2019, 24, 3006.	1.7	22
59	Design and synthesis of H <sub>2</sub> S-donor hybrids: A new treatment for Alzheimer's disease?. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111745.	2.6	49
60	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2876.	1.8	67
61	Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 66.	1.6	22
62	Memantine prodrug as a new agent for Alzheimer's Disease. <i>Scientific Reports</i> , 2019, 9, 4612.	1.6	54
63	Anticancer Effect of a Novel H <sub>2</sub> S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell Lines. , 2019, , 315-316.		0
64	First Examples of H <sub>2</sub> S-Releasing Glycoconjugates: Stereoselective Synthesis and Anticancer Activities. <i>Bioconjugate Chemistry</i> , 2019, 30, 614-620.	1.8	16
65	Anticancer properties of erucin, an H <sub>2</sub> S-releasing isothiocyanate, on human pancreatic adenocarcinoma cells (AsPC1). <i>Phytotherapy Research</i> , 2019, 33, 845-855.	2.8	61
66	Anticancer Activities of Erucin a H <sub>2</sub> S-Donor Isothiocyanate From Eruca Sativa Mill.: Is H <sub>2</sub> S the Real Player?. , 2019, , 327-328.		1
67	Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 745-754.	1.1	18
68	Mercaptopyruvate acts as endogenous vasodilator independently of 3-mercaptopyruvate sulfurtransferase activity. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 75, 53-59.	1.2	37
69	1,2,4-Thiadiazolidin-3,5-diones as novel hydrogen sulfide donors. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1677-1686.	2.6	38
70	The Role of Hydrogen Sulfide and H <sub>2</sub> S-donors in Myocardial Protection Against Ischemia/Reperfusion Injury. <i>Current Medicinal Chemistry</i> , 2018, 25, 4380-4401.	1.2	61
71	Efficacy of isothiocyanate-based compounds on different forms of persistent pain. <i>Journal of Pain Research</i> , 2018, Volume 11, 2905-2913.	0.8	19
72	Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5804-5815.	1.4	14

#	ARTICLE	IF	CITATIONS
73	Effect of glucoraphanin and sulforaphane against chemotherapy-induced neuropathic pain: Kv7 potassium channels modulation by H <sub>2</sub> S release <i>in vivo</i> . <i>Phytotherapy Research</i> , 2018, 32, 2226-2234.	2.8	61
74	Antioxidant and Antisenescence Effects of Bergamot Juice. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	42
75	Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs. <i>Current Medicinal Chemistry</i> , 2018, 25, 2661-2674.	1.2	11
76	The Renal Outer Medullary Potassium Channel (ROMK): An Intriguing Pharmacological Target for an Innovative Class of Diuretic Drugs. <i>Current Medicinal Chemistry</i> , 2018, 25, 2627-2636.	1.2	4
77	CHAPTER 8. Stevia rebaudiana Bertoni: Beyond Its Use as a Sweetener. Pharmacological and Toxicological Profile of Steviol Glycosides of Stevia rebaudiana Bertoni. <i>Food Chemistry, Function and Analysis</i> , 2018, , 148-161.	0.1	1
78	Effects of natural and synthetic isothiocyanate-based H <sub>2</sub> S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels. <i>Neuropharmacology</i> , 2017, 121, 49-59.	2.0	90
79	A Novel H <sub>2</sub> S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions. <i>Scientific Reports</i> , 2017, 7, 11940.	1.6	33
80	Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7512-7523.	2.9	48
81	Mitochondriotropic and Cardioprotective Effects of Triphenylphosphonium-Conjugated Derivatives of the Diterpenoid Isosteviol. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2060.	1.8	24
82	The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma. <i>Frontiers in Pharmacology</i> , 2017, 8, 65.	1.6	22
83	The Citrus Flavanone Naringenin Produces Cardioprotective Effects in Hearts from 1 Year Old Rat, through Activation of mitoBK Channels. <i>Frontiers in Pharmacology</i> , 2017, 8, 71.	1.6	39
84	Nutraceutical Value of Citrus Flavanones and Their Implications in Cardiovascular Disease. <i>Nutrients</i> , 2017, 9, 502.	1.7	121
85	The Citrus Flavanone Naringenin Protects Myocardial Cells against Age-Associated Damage. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-12.	1.9	58
86	Voltage-operated potassium (Kv) channels contribute to endothelium-dependent vasorelaxation of carvacrol on rat aorta. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1177-1183.	1.2	8
87	A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis. <i>ChemMedChem</i> , 2016, 11, 1804-1811.	1.6	6
88	The novel H <sub>2</sub> S-donor 4-carboxyphenyl isothiocyanate promotes cardioprotective effects against ischemia/reperfusion injury through activation of mitoK ATP channels and reduction of oxidative stress. <i>Pharmacological Research</i> , 2016, 113, 290-299.	3.1	71
89	Cystathionine $\beta$ -synthase-derived hydrogen sulfide is involved in human malignant hyperthermia. <i>Clinical Science</i> , 2016, 130, 35-44.	1.8	19
90	The novel H <sub>2</sub> S donor 4-carboxyphenyl isothiocyanate inhibits mast cell degranulation and renin release by decreasing intracellular calcium. <i>British Journal of Pharmacology</i> , 2016, 173, 3222-3234.	2.7	31

#	ARTICLE	IF	CITATIONS
91	Penicillamine modulates hydrogen sulfide ( $H_2S$ ) pathway through selective inhibition of cystathionine $\beta$ -lyase. <i>British Journal of Pharmacology</i> , 2016, 173, 1556-1565.	2.7	32
92	Using hydrogen sulfide to design and develop drugs. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 163-175.	2.5	49
93	Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection. <i>Cardiovascular Research</i> , 2016, 110, 40-50.	1.8	65
94	Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 422-428.	1.4	6
95	Inhibitors of the renal outer medullary potassium channel: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1035-1051.	2.4	9
96	Hydrogen sulfide inhalation ameliorates allergen induced airway hypereactivity by modulating mast cell activation. <i>Pharmacological Research</i> , 2015, 100, 85-92.	3.1	43
97	Different patterns of $H_2S/NO$ activity and cross-talk in the control of the coronary vascular bed under normotensive or hypertensive conditions. <i>Nitric Oxide - Biology and Chemistry</i> , 2015, 47, 25-33.	1.2	28
98	Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 274-288.	2.6	37
99	Mitochondrial Potassium Channels as Pharmacological Target for Cardioprotective Drugs. <i>Medicinal Research Reviews</i> , 2015, 35, 520-553.	5.0	63
100	Hydrogen Sulfide Releasing Capacity of Natural Isothiocyanates: Is It a Reliable Explanation for the Multiple Biological Effects of Brassicaceae?. <i>Planta Medica</i> , 2014, 80, 610-613.	0.7	86
101	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95.	1.3	44
102	Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. <i>Cardiovascular Research</i> , 2014, 102, 138-147.	1.8	88
103	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 772-786.	1.4	25
104	Pharmacological characterization of the vascular effects of aryl isothiocyanates: Is hydrogen sulfide the real player?. <i>Vascular Pharmacology</i> , 2014, 60, 32-41.	1.0	86
105	Arylthioamides as $H_2S$ Donors: Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 904-908.	1.3	144
106	1,4-Benzothiazine ATP-Sensitive Potassium Channel Openers: Modifications at the C-2 and C-6 Positions. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4718-4728.	2.9	20
107	Cardioprotective effects of different flavonoids against myocardial ischaemia/reperfusion injury in Langendorff-perfused rat hearts. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 750-756.	1.2	80
108	Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 693-699.	1.1	11

#	ARTICLE	IF	CITATIONS
109	The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury. <i>Biochemical Pharmacology</i> , 2013, 85, 1634-1643.	2.0	85
110	The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction. <i>Pharmacological Research</i> , 2013, 78, 1-9.	3.1	32
111	Large conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channel (BKCa) activating properties of a series of novel N-arylbenzamides: Channel subunit dependent effects. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4186-4191.	1.4	8
112	Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. <i>Pharmacological Research</i> , 2013, 70, 27-34.	3.1	105
113	Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3191-3206.	2.9	43
114	Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives. <i>Current Medicinal Chemistry</i> , 2012, 19, 3325-3336.	1.2	45
115	Hydrogen sulphide: novel opportunity for drug discovery. <i>Medicinal Research Reviews</i> , 2012, 32, 1093-1130.	5.0	144
116	Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cyclooxygenase-2 isoenzyme. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 287-298.	2.6	16
117	Differential Effects of Fondaparinux and Bemiparin on Angiogenic and Vasculogenesis-like processes. <i>Thrombosis Research</i> , 2012, 130, e113-e122.	0.8	6
118	Novel Analgesic/Anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7759-7771.	2.9	42
119	Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 966-973.	2.6	18
120	Hormonal influence on the release of endothelial nitric oxide: gender-related dimorphic sensitivity of rat aorta for noradrenaline. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 523-528.	1.2	15
121	Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 151-161.	1.2	23
122	Evaluation of the NO-releasing properties of NO-donor linkers. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 189-195.	1.2	6
123	Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 107-113.	1.2	6
124	Effects of K <sup>+</sup> ATP <sup>+</sup> openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 924-930.	1.2	14
125	Anti-ischemic properties of a new spiro-cyclic benzopyran activator of the cardiac mito-KATP channel. <i>Biochemical Pharmacology</i> , 2010, 79, 39-47.	2.0	35
126	Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6715-6724.	1.4	30



#	ARTICLE	IF	CITATIONS
127	Quantitative Structure–Activity Relationship Models for Predicting Biological Properties, Developed by Combining Structure- and Ligand-Based Approaches: An Application to the Human Ether-Go-Related Gene Potassium Channel Inhibition. <i>Chemical Biology and Drug Design</i> , 2009, 74, 416-433.		6
128	QSAR studies on BK channel activators. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 319-325.	1.4	16
129	Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5565-5571.	1.4	26
130	NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5426-5432.	1.4	28
131	Enantioselectivity in Cardioprotection induced by (S)-( $\hat{\alpha}$ )-2,2-Dimethyl-N-(4-acetamido-benzyl)-4-spiromorpholone-chromane. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1477-1480.	2.9	14
132	Pharmacodynamic Hybrids Coupling Established Cardiovascular Mechanisms of Action with Additional Nitric Oxide Releasing Properties. <i>Current Pharmaceutical Design</i> , 2009, 15, 614-636.	0.9	28
133	New amido derivatives as potential BKCa potassium channel activators. XI. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 792-799.	2.6	2
134	N6-1,3-Diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: Synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1639-1647.	2.6	26
135	Identification of $\alpha$ -toxicophoric features for predicting drug-induced QT interval prolongation. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2479-2488.	2.6	18
136	1,2,3-Triazol-carboxanilides and 1,2,3-triazol-(N-benzyl)-carboxamides as BK-potassium channel activators. XII. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2618-2626.	2.6	20
137	Spirocyclic Benzopyran-Based Derivatives as New Anti-ischemic Activators of Mitochondrial ATP-Sensitive Potassium Channel. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6945-6954.	2.9	25
138	An update on hybrid drugs in cardiovascular drug research. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1397-1408.	2.5	4
139	Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca <sup>2+</sup> -Activated Potassium Channel Openers. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5085-5092.	2.9	29
140	New Emerging Prospects in the Pharmacotherapy of Hypertension. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008, 6, 1-19.	0.4	6
141	Novel N-Substituted Indol-3-ylglyoxylamides Probing the L1 and L2 Lipophilic Regions of the Benzodiazepine Receptor Site in Search for Subtype-Selective Ligands. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1627-1634.	2.9	21
142	QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II. <i>Journal of Applied Toxicology</i> , 2007, 27, 270-275.	1.4	15
143	In vivo adenosine A2B receptor desensitization in guinea-pig airway smooth muscle: Implications for asthma. <i>European Journal of Pharmacology</i> , 2007, 575, 149-157.	1.7	11
144	Functional contribution of the endothelial component to the vasorelaxing effect of resveratrol and NS 1619, activators of the large-conductance calcium-activated potassium channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 375, 73-80.	1.4	20

#	ARTICLE	IF	CITATIONS
145	Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists: A Homology Modeling, Docking and Three-Dimensional Quantitative Structure-Activity Relationship Analysis. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4305-4316.	2.9	72
146	New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7600-7602.	2.9	46
147	(+/-)-Naringenin as large conductance Ca <sup>2+</sup> -activated K <sup>+</sup> (BK Ca <sup>2+</sup> ) channel opener in vascular smooth muscle cells. <i>British Journal of Pharmacology</i> , 2006, 149, 1013-1021.	2.7	109
148	Heterocyclic analogs of benzanilide derivatives as potassium channel activators. IX. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 761-767.	2.6	24
149	Structural modifications of benzanilide derivatives, effective potassium channel openers. X.. <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 1421-1429.	2.6	20
150	Prediction of hERG potassium channel affinity by the CODESSA approach. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3153-3159.	1.4	56
151	New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: A Design, Synthesis, and Biopharmacological Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2628-2639.	2.9	54
152	Editorial [Hot Topic: Potassium Channels (Guest Editor: Dr. Vincenzo Calderone)]. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 997-998.	1.0	1
153	NO-Releasing Hybrids of Cardiovascular Drugs. <i>Current Medicinal Chemistry</i> , 2006, 13, 609-625.	1.2	33
154	Potassium Channel Openers: The Case of BK Channel Activators. <i>Letters in Drug Design and Discovery</i> , 2006, 3, 210-218.	0.4	17
155	Benzoyl and/or benzyl substituted 1,2,3-triazoles as potassium channel activators. VIII. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 521-528.	2.6	47
156	1,4- and 2,4-substituted-1,2,3-triazoles as potential potassium channel activators. VII. <i>Il Farmaco</i> , 2005, 60, 367-375.	0.9	10
157	1,4- and 2,4-Substituted-1,2,3-triazoles as Potential Potassium Channel Activators. Part 7.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
158	Benzoyl and/or Benzyl Substituted 1,2,3-Triazoles as Potassium Channel Activators. Part 8.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
159	Morphiceptin Analogues Containing a Dipeptide Mimetic Structure: An Investigation on the Bioactive Topology at the $\mu$ -Receptor. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3153-3163.	2.9	16
160	Torsadogenic Cardiotoxicity of Antipsychotic Drugs: a Structural Feature, Potentially Involved in the Interaction with Cardiac hERG Potassium Channels. <i>Current Medicinal Chemistry</i> , 2004, 11, 2691-2706.	1.2	48
161	1,5-Diarylsubstituted 1,2,3-triazoles as potassium channel activators. VI. <i>Il Farmaco</i> , 2004, 59, 397-404.	0.9	44
162	Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 290-298.	1.4	121

#	ARTICLE	IF	CITATIONS
163	QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. <i>Journal of Applied Toxicology</i> , 2004, 24, 217-222.	1.4	42
164	1,5-Diarylsubstituted 1,2,3-Triazoles as Potassium Channel Activators. Part 6.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
165	Synthesis and Biological Activity of Novel Substituted Benzanilides as Potassium Channel Activators. Part 5.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
166	Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1921-1933.	1.4	36
167	Synthesis and biological activity of novel substituted benzanilides as potassium channel activators. V. <i>European Journal of Medicinal Chemistry</i> , 2004, 39, 491-498.	2.6	42
168	NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5597-5600.	2.9	45
169	Vasodilator activity of <i>Michelia figo</i> Spreng. (Magnoliaceae) by in vitro functional study. <i>Journal of Ethnopharmacology</i> , 2004, 91, 263-266.	2.0	13
170	R(+)-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. <i>European Journal of Pharmacology</i> , 2003, 459, 75-81.	1.7	9
171	Synthesis and $\beta$ -blocking activity of (R, S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]pyridine: identification of $\beta$ -3-antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4921-4931.	1.4	16
172	Highly Potent 1,4-Benzothiazine Derivatives as KATP-Channel Openers. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3670-3679.	2.9	48
173	The Xanthones Gentiacaulein and Gentiakochianin are Responsible for the Vasodilator Action of the Roots of <i>Gentiana kochiana</i> . <i>Planta Medica</i> , 2003, 69, 770-772.	0.7	21
174	Natural Modulators of Large-Conductance Calcium-Activated Potassium Channels. <i>Planta Medica</i> , 2003, 69, 885-892.	0.7	43
175	Large-Conductance, Ca <sup>2+</sup> -Activated K <sup>+</sup> Channels: Function, Pharmacology and Drugs. <i>Current Medicinal Chemistry</i> , 2002, 9, 1385-1395.	1.2	97
176	Vasodilator activity of crude methanolic extract of <i>Gentiana kokiana</i> Perr. et Song. (Gentianaceae). <i>Journal of Ethnopharmacology</i> , 2002, 79, 369-372.	2.0	13
177	Cardiovascular effects of <i>Urtica dioica</i> L. (Urticaceae) roots extracts: in vitro and in vivo pharmacological studies. <i>Journal of Ethnopharmacology</i> , 2002, 81, 105-109.	2.0	102
178	Conformationally restrained analogues of sympathomimetic catecholamines. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 11-22.	2.6	4
179	Synthesis and evaluation of antihypertensive activity of 1,8-naphthyridine derivatives. Part X. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 925-934.	2.6	28
180	Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO. <i>British Journal of Pharmacology</i> , 2001, 134, 745-752.	2.7	11

#	ARTICLE	IF	CITATIONS
181	New 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, potassium channel activators. IV. <i>Il Farmaco</i> , 2001, 56, 827-834.	0.9	23
182	Some structural changes on triazolyl-benzotriazoles and triazolyl-benzimidazolones as potential potassium channel activators. III. <i>Il Farmaco</i> , 2001, 56, 841-849.	0.9	29
183	1-(1,2,3-triazol-4-yl)-benzimidazolones, a new series of heterocyclic derivatives. <i>Journal of Heterocyclic Chemistry</i> , 2000, 37, 1169-1176.	1.4	10
184	Triazolyl-benzimidazolones and triazolyl-benzotriazoles: new potential potassium channel activators. II. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 949-955.	2.6	29
185	Synthesis and $\beta$ -blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]pyridine: potential antihypertensive agents Part IX. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 815-826.	2.6	94
186	5-(4-Substituted-2-nitroanilino)-1,2,3-triazoles as new potential potassium channel activators. I. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 715-720.	2.6	36
187	Synthesis of 1,8-naphthyridine derivatives: potential antihypertensive agents Part VIII. <i>European Journal of Medicinal Chemistry</i> , 1999, 34, 505-513.	2.6	17
188	Experimental and theoretical comparisons between the classical Schild analysis and a new alternative method to evaluate the pA <sub>2</sub> of competitive antagonists. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999, 360, 477-487.	1.4	3
189	Condensation of substituted 2-aminopyridine with $\beta$ -keto-carboxylic esters: 4-H-pyrido[1,2-a]pyrimidinones and pyridinones. <i>Journal of Heterocyclic Chemistry</i> , 1999, 36, 1123-1127.		5
190	Antiviral properties of a crude extract from a green alga <i>Caulerpa taxifolia</i> (Vahl) C. Agardh. , 1999, 13, 245-247.		20
191	Vascular effects of aqueous crude extracts of <i>Artemisia verlotorum</i> Lamotte (Compositae): in vivo and in vitro pharmacological studies in rats. , 1999, 13, 645-648.		22
192	Stereoselective synthesis and $\beta$ -blocking activity of substituted (E)- and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl)oximino]-2,3-dihydro-1,8-naphthyridine. Potential antihypertensive agents. Part VI. <i>European Journal of Medicinal Chemistry</i> , 1998, 32, 955-963.	2.6	15
193	An alternative method to evaluate the nature of an antagonist and its potency: a theoretical approach. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 39, 129-135.	0.3	3
194	A simplified empirical approach to evaluate the dissociation constant of a full agonist by the irreversible receptor inactivation method. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 40, 57-62.	0.3	2
195	Intrinsic activity and EC <sub>50</sub> : the simplest tools for the evaluation of the dissociation constant of a partial agonist. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 40, 207-210.	0.3	2
196	In vitro antiviral effects of an aqueous extract of <i>Artemisia verlotorum</i> Lamotte (Asteraceae). , 1998, 12, 595-597.		7
197	Influence of depolarization on vasorelaxant potency and efficacy of Ca <sup>2+</sup> entry blockers, K <sup>+</sup> channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 358, 452-463.	1.4	29
198	Synthesis of 1,8-naphthyridine derivatives: Potential antihypertensive agents Part VII. <i>European Journal of Medicinal Chemistry</i> , 1998, 33, 383-397.	2.6	49

#	ARTICLE	IF	CITATIONS
199	Synthesis and $\hat{1}\pm$ -adrenergic and I1-imidazoline activity of 3-phenylpiperidines dimethyl-substituted on the phenyl ring. <i>European Journal of Medicinal Chemistry</i> , 1998, 33, 911-919.	2.6	6
200	Pharmacological action of aqueous crude extracts of <i>Artemisia verlotorum</i> Lamotte (Compositae)., 1997, 11, 612-614.		4
201	A modified aortic multiple-ring preparation for functional studies. <i>Journal of Pharmacological and Toxicological Methods</i> , 1996, 35, 131-138.	0.3	17
202	Epi-Drugs in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	17